Senile DeadnessNCT07389213
Efficacy and Safety of rTMS Combined With HA in the Treatment of Cognitive Decline in Aged Related Hearing Loss
A study testing repetitive Transcranial Magnetic Stimulation (rTMS) in people with Senile Deadness, run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University at 1 site in China.
Trial summary
This study is a real-world interventional trial enrolling 189 participants: older adults with age-related hearing loss not using hearing aids (ARHL-nonHA), those using hearing aids (ARHL-HA), and those with normal hearing (HC). Read more about this study
- Who is it for?
- Ages 50 to 85 yearsHealthy volunteers can take part
- Conditions the study is for
- Senile Deadness
- What is being tested?
- repetitive Transcranial Magnetic Stimulation (rTMS)
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 189 participants
- Where
- 1 siteChina
- Study dates
- 1 May 2025to 31 Aug 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 85 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Age ≥50 years and ≤85 years, regardless of gender.
- Diagnosed with age-related hearing loss (ARHL), characterized by symmetrical, slowly progressing hearing loss primarily affecting high frequencies, along with decreased speech recognition ability due to aging. This is in accordance with the "Expert Consensus on Diagnosis and Intervention of Age-Related Hearing Loss" 2019 edition.(Only ARHL-nonHA group and ARHL-HA group)
- The better ear has moderate, moderately severe, or severe hearing loss (based on the 2021 WHO hearing classification standards, i.e., PTA between 35～79dB).
- Wearing hearing aids for more than half a year, with daily wearing time exceeding 7.2 hours; (Only ARHL-HA group)
- Chinese nationals who can complete all assessments in Chinese.
- Right-handed.
- Educational level of at least 6 years.
- Informed consent obtained, agreeing to participate in the trial with no plans to relocate within one year.
Who cannot join
- Exclusion of hearing loss due to noise, genetics, ototoxic drugs, or other non-age-related causes;
- History of central nervous system disorders such as cerebral infarction, stroke, epilepsy, or traumatic brain injury;
- Diagnosis of dementia or other neurodegenerative diseases that affect compliance with the study;
- Presence of major neurological disorders, severe systemic diseases, family history of hereditary conditions, or major psychiatric disorders;
- Contraindications to MRI;
- Contraindications to rTMS.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Sun Yat-sen Memorial Hospital of Sun Yat-sen University
Guangzhou, Guangdong, 5100000
Haidi Yang, PhD, 020-81332449, yanghaidi1978@163.com
About this study
Official title: Efficacy and Safety of rTMS Combined With HA in the Treatment of Cognitive Decline in Aged Related Hearing Loss: A Single-Center Real-World Study
This study is a real-world interventional trial enrolling 189 participants: older adults with age-related hearing loss not using hearing aids (ARHL-nonHA), those using hearing aids (ARHL-HA), and those with normal hearing (HC). All groups will undergo hearing, cognitive (MMSE, MoCA, SCWT, DST, TMT), depression (GDS-15, HAMD-24), sleep (PSQI), and brain imaging (EEG, sMRI, rs-fMRI, task-fMRI) assessments. The ARHL-nonHA and ARHL-HA groups will receive two 14-day courses of high-frequency rTMS (one session daily). One month after treatment, reassessments will be conducted in these two groups. Data will then be analyzed to evaluate the cognitive benefits of rTMS combined with hearing aids and to explore the underlying brain mechanisms.
Read the detailed description
This study plans to conduct an interventional real-world study, enrolling 189 participants according to inclusion and exclusion criteria, including elderly patients with age-related hearing loss who do not wear hearing aids (ARHL-nonHA group), elderly patients with age-related hearing loss who wear hearing aids (ARHL-HA group), and elderly individuals with normal hearing (HC group). Audiological assessments (pure-tone average PTA, speech recognition threshold SRT), cognitive function assessments (Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Stroop Color-Word Test(SCWT), Digit Span Test (DST), Trail Making Test A (TMT-A), Trail Making Test B(TMT-B)), depression and sleep assessments (Geriatric Depression Scale (GDS-15), Hamilton Depression Rating Scale (HAMD-24), Pittsburgh Sleep Quality Index (PSQI)), and imaging assessments (resting-state (EEG), structural (sMRI), resting-state functional (rs-fMRI), task-based functional (task-fMRI)) will be performed on these three groups of participants. The ARHL-nonHA group and the ARHL-HA group will receive high-frequency repetitive Transcranial Magnetic Stimulation(rTMS) for two treatment courses, with each course lasting 14 days and one session per day. One month later, audiometric, cognitive, and imaging assessments will be repeated for the ARHL-nonHA and ARHL-HA groups. After the study, data will be collected and analyzed to evaluate the improvement effects of rTMS combined with HA on cognitive function in elderly patients with hearing loss, as well as its underlying brain functional mechanisms.
- Conditions
- Senile Deadness
- Being tested
- repetitive Transcranial Magnetic Stimulation (rTMS)
- Keywords
- senile deadness
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
repetitive Transcranial Magnetic Stimulation (rTMS)Device
High-frequency repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation technique that modulates neural activity by delivering magnetic pulses to specific regions of the cerebral cortex. In this study, 50 Hz high-frequency stimulation will be used to enhance neuronal excitability, with stimulation intensity set at 80%-100% of the individual's motor threshold (MT) to accommodate the tolerance of elderly patients. Using each participant's MRI for neuronavigation, the stimulation coil will be precisely positioned over the left dorsolateral prefrontal cortex (DLPFC). Stimulation will be administered while the patient is awake, with each session lasting 9 minutes, delivered once daily. A single treatment course consists of 14 consecutive days, and a total of two courses will be conducted. Patient status will be closely monitored throughout the intervention to ensure safety and accuracy.
| Study group | Role | What they receive |
|---|---|---|
| ARHL-nonHA group | Experimental | This study will use repetitive transcranial magnetic stimulation (rTMS) as an intervention. Participants will be right-handed Chinese individuals aged between 50 and 85 years, diagnosed with moderate to severe age-related hearing loss (pure-tone average PTA of the better ear ranging from 35 to 79 dB), meeting the diagnostic criteria outlined in the 2019 expert consensus. Eligible participants must have at least 6 years of education and be able to complete all assessments in the Chinese version. Receives: Device: repetitive Transcranial Magnetic Stimulation (rTMS) |
| ARHL-HA group | Experimental | This study will use repetitive transcranial magnetic stimulation (rTMS) as an intervention. Participants will be right-handed Chinese individuals aged between 50 and 85 years, diagnosed with moderate to severe age-related hearing loss (pure-tone average PTA of the better ear ranging from 35 to 79 dB).Participants must have been wearing hearing aids for more than six months and use them for over 7.2 hours daily. Eligible participants must have at least 6 years of education and be able to complete all assessments in the Chinese version. Receives: Device: repetitive Transcranial Magnetic Stimulation (rTMS) |
| HC group | No intervention | Aged between 50 and 85 years, with no gender restriction; pure-tone average (PTA) ≤25 dB HL in the better ear; Chinese nationality, able to complete all Chinese-version assessments; right-handed; and with at least 6 years of education. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Montreal Cognitive Assessment(MoCA ) improvement value
The Montreal Cognitive Assessment (MoCA) ranges from 0 to 30, with higher scores indicating better cognitive function; a score of 26 or above is generally considered normal.
The overall cognitive function in all groups with hearing loss was assessed using the MoCA scale before and after intervention, and the difference was calculated.
Measured: Baseline、Post-intervention 2 weeks and Post-intervention 1 month
Secondary outcomes (10)
Mini-Mental State Examination(MMSE) improvement value
The Mini-Mental State Examination (MMSE) is scored on a scale from 0 to 30, with higher scores indicating better cognitive function.
Overall cognitive function was assessed in all groups using the MMSE before and after the intervention, and the change scores were calculated.
Measured: Baseline、Post-intervention 2 weeks and Post-intervention 1 month
Pure-Tone Average(PTA) improvement value
The Pure-Tone Average (PTA) is calculated as the mean hearing threshold (in decibels hearing level, dB HL) at 500 Hz, 1 kHz, 2 kHz, and 4 kHz before and after intervention in the ARHL-HA group and the ARHL-nonHA group was assessed using pure-tone audiometry and sound field audiometry, and the difference was calculated.
Measured: Baseline、Post-intervention 2 weeks and Post-intervention 1 month
Speech Reception Threshold(SRT) improvement value
The Speech Reception Threshold (SRT) is the lowest intensity levelat which a person correctly identifies 50% of spondaic (two-syllable) words were correctly identified before and after intervention in the ARHL-HA group and the ARHL-nonHA group was assessed using speech audiometry and sound field speech audiometry, and the difference was calculated.
Measured: Baseline、Post-intervention 2 weeks and Post-intervention 1 month
Trail Making Test Part A (TMT-A) improvement value
The Trail Making Test Part A (TMT-A) is scored based on the time (in seconds) required to complete the task, with lower scores indicating better attention and information processing speed.
The attention and information processing speed in the ARHL-HA group and the ARHL-nonHA group were assessed using the TMT-A before and after intervention, and the difference was calculated.
Measured: Baseline、Post-intervention 2 weeks and Post-intervention 1 month
Trail Making Test Part B (TMT-B) improvement value
The Trail Making Test Part B (TMT-B) is scored based on the time (in seconds) required to complete the task, with lower scores indicating better set-shifting ability and executive function.
The set-shifting component of executive function in the ARHL-HA group and the ARHL-nonHA group was assessed using the TMT-B before and after intervention, and the difference was calculated.
Measured: Baseline、Post-intervention 2 weeks and Post-intervention 1 month
Digit Span Test (DST)improvement value
The Digit Span Test (DST) is scored as the total number of correctly recalled digit sequences, with a typical total raw score ranging from 0 to 8. Higher scores indicate better attention, short-term memory, and working memory.
Attention, short-term memory, and working memory in the ARHL-HA group and the ARHL-nonHA group were assessed using the DST before and after intervention, and the difference was calculated.
Measured: Baseline、Post-intervention 2 weeks and Post-intervention 1 month
Stroop Color and Word Test (SCWT) improvement value
The Stroop Color and Word Test (SCWT) is typically scored based on the time (in seconds) required to complete specific conditions .Lower completion times or lower interference scores indicate better inhibitory control and faster information processing speed, meaning lower values represent a better outcome.
The inhibitory control of dominant responses and information processing speed, as components of executive function, in the ARHL-HA group and the ARHL-nonHA group were assessed using the SCWT before and after intervention, and the difference was calculated.
Measured: Baseline、Post-intervention 2 weeks and Post-intervention 1 month
15-item Geriatric Depression Scale (GDS-15) improvement value
The 15-item Geriatric Depression Scale (GDS-15) is scored by summing the number of depressive symptom responses, with total scores ranging from 0 (no depressive symptoms) to 15 (most severe depressive symptoms). Higher scores indicate greater severity of depressive symptoms.
Depressive symptom scores in the ARHL-HA group and the ARHL-nonHA group were assessed using the GDS-15 before and after intervention, and the difference was calculated.
Measured: Baseline、Post-intervention 2 weeks and Post-intervention 1 month
24-item Hamilton Depression Rating Scale (HAMD-24)improvement value
The 24-item Hamilton Depression Rating Scale (HAMD-24) is a clinician-administered measure of depressive symptom severity, with total scores ranging from 0 to 76. Higher scores indicate more severe depression.
Depressive symptom scores in the ARHL-HA group and the ARHL-nonHA group were assessed using the HAMD-24 before and after intervention, and the difference was calculated.
Measured: Baseline、Post-intervention 2 weeks and Post-intervention 1 month
Pittsburgh Sleep Quality Index (PSQI) improvement value
The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire that assesses sleep quality and disturbances over a one-month period. Total scores range from 0 to 21, with higher scores indicating poorer sleep quality.
Sleep scores in the ARHL-HA group and the ARHL-nonHA group were assessed using the PSQI before and after intervention, and the difference was calculated.
Measured: Baseline、Post-intervention 2 weeks and Post-intervention 1 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Feb 2026
- Study start1 May 2025
- Primary completion23 Jul 2026 (estimated)
- Study completion31 Aug 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Senile DeadnessStudies of the same condition, open and under way.
- More trials run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- A total of 189 participants will be enrolled according to inclusion and exclusion criteria, including the ARHL-nonHA group, the ARHL-HA group, and the HC group. The three groups will undergo audiological assessments (PTA, SRT), cognitive function assessments (MoCA, MMSE, TMT-A, TMT-B, DST, SCWT), depression and sleep assessments (GDS-15, HAMD-24, PSQI), and imaging assessments (resting-state EEG, structural sMRI, resting-state functional rs-fMRI, task-based functional task-fMRI). The ARHL-nonHA and ARHL-HA groups will receive two courses of high-frequency rTMS stimulation, with each course lasting 14 days, one session per day, and each session lasting 9 minutes. Audiological, cognitive, depression and sleep, and imaging assessments will be performed on the ARHL-nonHA and ARHL-HA groups at 14 days and 1 month after the intervention, and the improvement values of the above indicators will be obtained.
- Masking
- None (open label)
- Enrolment
- 189 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Yang Haidi, PhD, Study chair, SunYatSunU2H
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07389213
- Sponsor's protocol ID
- SYSKY-2025-525-01
- Status last verified
- Jul 2025
- First submitted
- 25 Nov 2025
- Last updated
- 5 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy and Safety of rTMS Combined With HA in the Treatment of Cognitive Decline in Aged Related Hearing Loss: A Single-Center Real-World Study
- ClinicalTrials.gov ID
- NCT07389213
- Acronym / sponsor ID
- SYSKY-2025-525-01
- Conditions
- Senile Deadness
- Keywords
- senile deadness
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 189 participants (estimated)
- Lead sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityUniversity, hospital or other
- Study start
- 1 May 2025 (actual)
- Primary completion
- 23 Jul 2026 (estimated)
- Study completion
- 31 Aug 2028 (estimated)
- First posted
- 5 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a real-world interventional trial enrolling 189 participants: older adults with age-related hearing loss not using hearing aids (ARHL-nonHA), those using hearing aids (ARHL-HA), and those with normal hearing (HC). All groups will undergo hearing, cognitive (MMSE, MoCA, SCWT, DST, TMT), depression (GDS-15, HAMD-24), sleep (PSQI), and brain imaging (EEG, sMRI, rs-fMRI, task-fMRI) assessments. The ARHL-nonHA and ARHL-HA groups will receive two 14-day courses of high-frequency rTMS (one session daily). One month after treatment, reassessments will be conducted in these two groups. Data will then be analyzed to evaluate the cognitive benefits of rTMS combined with hearing aids and to explore the underlying brain mechanisms.
Detailed description
This study plans to conduct an interventional real-world study, enrolling 189 participants according to inclusion and exclusion criteria, including elderly patients with age-related hearing loss who do not wear hearing aids (ARHL-nonHA group), elderly patients with age-related hearing loss who wear hearing aids (ARHL-HA group), and elderly individuals with normal hearing (HC group). Audiological assessments (pure-tone average PTA, speech recognition threshold SRT), cognitive function assessments (Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Stroop Color-Word Test(SCWT), Digit Span Test (DST), Trail Making Test A (TMT-A), Trail Making Test B(TMT-B)), depression and sleep assessments (Geriatric Depression Scale (GDS-15), Hamilton Depression Rating Scale (HAMD-24), Pittsburgh Sleep Quality Index (PSQI)), and imaging assessments (resting-state (EEG), structural (sMRI), resting-state functional (rs-fMRI), task-based functional (task-fMRI)) will be performed on these three groups of participants. The ARHL-nonHA group and the ARHL-HA group will receive high-frequency repetitive Transcranial Magnetic Stimulation(rTMS) for two treatment courses, with each course lasting 14 days and one session per day. One month later, audiometric, cognitive, and imaging assessments will be repeated for the ARHL-nonHA and ARHL-HA groups. After the study, data will be collected and analyzed to evaluate the improvement effects of rTMS combined with HA on cognitive function in elderly patients with hearing loss, as well as its underlying brain functional mechanisms.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
- Model description
- A total of 189 participants will be enrolled according to inclusion and exclusion criteria, including the ARHL-nonHA group, the ARHL-HA group, and the HC group. The three groups will undergo audiological assessments (PTA, SRT), cognitive function assessments (MoCA, MMSE, TMT-A, TMT-B, DST, SCWT), depression and sleep assessments (GDS-15, HAMD-24, PSQI), and imaging assessments (resting-state EEG, structural sMRI, resting-state functional rs-fMRI, task-based functional task-fMRI). The ARHL-nonHA and ARHL-HA groups will receive two courses of high-frequency rTMS stimulation, with each course lasting 14 days, one session per day, and each session lasting 9 minutes. Audiological, cognitive, depression and sleep, and imaging assessments will be performed on the ARHL-nonHA and ARHL-HA groups at 14 days and 1 month after the intervention, and the improvement values of the above indicators will be obtained.
| Arm | Type | Receives |
|---|---|---|
| ARHL-nonHA group | Experimental | Device: repetitive Transcranial Magnetic Stimulation (rTMS)This study will use repetitive transcranial magnetic stimulation (rTMS) as an intervention. Participants will be right-handed Chinese individuals aged between 50 and 85 years, diagnosed with moderate to severe age-related hearing loss (pure-tone average PTA of the better ear ranging from 35 to 79 dB), meeting the diagnostic criteria outlined in the 2019 expert consensus. Eligible participants must have at least 6 years of education and be able to complete all assessments in the Chinese version. |
| ARHL-HA group | Experimental | Device: repetitive Transcranial Magnetic Stimulation (rTMS)This study will use repetitive transcranial magnetic stimulation (rTMS) as an intervention. Participants will be right-handed Chinese individuals aged between 50 and 85 years, diagnosed with moderate to severe age-related hearing loss (pure-tone average PTA of the better ear ranging from 35 to 79 dB).Participants must have been wearing hearing aids for more than six months and use them for over 7.2 hours daily. Eligible participants must have at least 6 years of education and be able to complete all assessments in the Chinese version. |
| HC group | No intervention | –Aged between 50 and 85 years, with no gender restriction; pure-tone average (PTA) ≤25 dB HL in the better ear; Chinese nationality, able to complete all Chinese-version assessments; right-handed; and with at least 6 years of education. |
Who may qualify
- Ages
- 50 to 85 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Age ≥50 years and ≤85 years, regardless of gender.
- Diagnosed with age-related hearing loss (ARHL), characterized by symmetrical, slowly progressing hearing loss primarily affecting high frequencies, along with decreased speech recognition ability due to aging. This is in accordance with the "Expert Consensus on Diagnosis and Intervention of Age-Related Hearing Loss" 2019 edition.(Only ARHL-nonHA group and ARHL-HA group)
- The better ear has moderate, moderately severe, or severe hearing loss (based on the 2021 WHO hearing classification standards, i.e., PTA between 35～79dB).
- Wearing hearing aids for more than half a year, with daily wearing time exceeding 7.2 hours; (Only ARHL-HA group)
- Chinese nationals who can complete all assessments in Chinese.
Key exclusion criteria (6 listed)
- Exclusion of hearing loss due to noise, genetics, ototoxic drugs, or other non-age-related causes;
- History of central nervous system disorders such as cerebral infarction, stroke, epilepsy, or traumatic brain injury;
- Diagnosis of dementia or other neurodegenerative diseases that affect compliance with the study;
- Presence of major neurological disorders, severe systemic diseases, family history of hereditary conditions, or major psychiatric disorders;
- Contraindications to MRI;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| repetitive Transcranial Magnetic Stimulation (rTMS)High-frequency repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation technique that modulates neural activity by delivering magnetic pulses to specific regions of the cerebral cortex. In this study, 50 Hz high-frequency stimulation will be used to enhance neuronal excitability, with stimulation intensity set at 80%-100% of the individual's motor threshold (MT) to accommodate the tolerance of elderly patients. Using each participant's MRI for neuronavigation, the stimulation coil will be precisely positioned over the left dorsolateral prefrontal cortex (DLPFC). Stimulation will be administered while the patient is awake, with each session lasting 9 minutes, delivered once daily. A single treatment course consists of 14 consecutive days, and a total of two courses will be conducted. Patient status will be closely monitored throughout the intervention to ensure safety and accuracy. | Device | ARHL-HA group, ARHL-nonHA group |
Primary outcome
Montreal Cognitive Assessment(MoCA ) improvement value
Time frame: Baseline、Post-intervention 2 weeks and Post-intervention 1 month
The Montreal Cognitive Assessment (MoCA) ranges from 0 to 30, with higher scores indicating better cognitive function; a score of 26 or above is generally considered normal. The overall cognitive function in all groups with hearing loss was assessed using the MoCA scale before and after intervention, and the difference was calculated.
10 secondary outcomes
Mini-Mental State Examination(MMSE) improvement value
Time frame: Baseline、Post-intervention 2 weeks and Post-intervention 1 month
Pure-Tone Average(PTA) improvement value
Time frame: Baseline、Post-intervention 2 weeks and Post-intervention 1 month
Speech Reception Threshold(SRT) improvement value
Time frame: Baseline、Post-intervention 2 weeks and Post-intervention 1 month
Trail Making Test Part A (TMT-A) improvement value
Time frame: Baseline、Post-intervention 2 weeks and Post-intervention 1 month
Trail Making Test Part B (TMT-B) improvement value
Time frame: Baseline、Post-intervention 2 weeks and Post-intervention 1 month
Digit Span Test (DST)improvement value
Time frame: Baseline、Post-intervention 2 weeks and Post-intervention 1 month
Stroop Color and Word Test (SCWT) improvement value
Time frame: Baseline、Post-intervention 2 weeks and Post-intervention 1 month
15-item Geriatric Depression Scale (GDS-15) improvement value
Time frame: Baseline、Post-intervention 2 weeks and Post-intervention 1 month
24-item Hamilton Depression Rating Scale (HAMD-24)improvement value
Time frame: Baseline、Post-intervention 2 weeks and Post-intervention 1 month
Pittsburgh Sleep Quality Index (PSQI) improvement value
Time frame: Baseline、Post-intervention 2 weeks and Post-intervention 1 month
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Feb 2026.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Yang Haidi, PhD study chair
SunYatSunU2H
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing repetitive Transcranial Magnetic Stimulation (rTMS) in people with Senile Deadness, run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 5 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Yang Haidi, PhD (13178821663, yanghaidi1978@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Montreal Cognitive Assessment(MoCA ) improvement value (time frame: Baseline、Post-intervention 2 weeks and Post-intervention 1 month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Feb 2026.